A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of the Efficacy and Safety of MK-8189 Using Risperidone as an Active Control in Subjects Experiencing an Acute Episode of Schizophrenia

Trial Profile

A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of the Efficacy and Safety of MK-8189 Using Risperidone as an Active Control in Subjects Experiencing an Acute Episode of Schizophrenia

Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Aug 2017

At a glance

  • Drugs MK 8189 (Primary) ; Risperidone
  • Indications Schizophrenia
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms MK-8189-005
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 25 Jul 2017 Planned End Date changed from 8 May 2018 to 1 Dec 2017.
    • 25 Jul 2017 Planned primary completion date changed from 8 May 2018 to 1 Dec 2017.
    • 17 Mar 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top